These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 30261007)

  • 1. Efficacy of pyrazinoic acid dry powder aerosols in resolving necrotic and non-necrotic granulomas in a guinea pig model of tuberculosis.
    Montgomery SA; Young EF; Durham PG; Zulauf KE; Rank L; Miller BK; Hayden JD; Lin FC; Welch JT; Hickey AJ; Braunstein M
    PLoS One; 2018; 13(9):e0204495. PubMed ID: 30261007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhaled Pyrazinoic Acid Esters for the Treatment of Tuberculosis.
    Young EF; Perkowski E; Malik S; Hayden JD; Durham PG; Zhong L; Welch JT; Braunstein MS; Hickey AJ
    Pharm Res; 2016 Oct; 33(10):2495-505. PubMed ID: 27351427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Phenotypic characterization of pyrazinamide-resistant Mycobacterium tuberculosis isolated in Poland].
    Napiórkowska A; Augustynowicz-Kopeć E; Zwolska Z
    Pneumonol Alergol Pol; 2010; 78(4):256-62. PubMed ID: 20665445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dry powder PA-824 aerosols for treatment of tuberculosis in guinea pigs.
    Garcia-Contreras L; Sung JC; Muttil P; Padilla D; Telko M; Verberkmoes JL; Elbert KJ; Hickey AJ; Edwards DA
    Antimicrob Agents Chemother; 2010 Apr; 54(4):1436-42. PubMed ID: 20086154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic Considerations for Optimizing Inhaled Spray-Dried Pyrazinoic Acid Formulations.
    Yeshwante SB; Hanafin P; Miller BK; Rank L; Murcia S; Xander C; Annis A; Baxter VK; Anderson EJ; Jermain B; Konicki R; Schmalstig AA; Stewart I; Braunstein M; Hickey AJ; Rao GG
    Mol Pharm; 2023 Sep; 20(9):4491-4504. PubMed ID: 37590399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spray Dried Aerosol Particles of Pyrazinoic Acid Salts for Tuberculosis Therapy. [Corrected].
    Durham PG; Zhang Y; German N; Mortensen N; Dhillon J; Mitchison DA; Fourie PB; Hickey AJ
    Mol Pharm; 2015 Aug; 12(8):2574-81. PubMed ID: 26098136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel inexpensive electrochemical sensor for pyrazinoic acid as a potential tool for the identification of pyrazinamide-resistant
    Rueda D; Furukawa R; Fuentes P; Comina G; Rey De Castro NG; Requena D; Gilman RH; Sheen P; Zimic M
    Int J Mycobacteriol; 2018; 7(3):275-281. PubMed ID: 30198510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tuberculosis drugs' distribution and emergence of resistance in patient's lung lesions: A mechanistic model and tool for regimen and dose optimization.
    Strydom N; Gupta SV; Fox WS; Via LE; Bang H; Lee M; Eum S; Shim T; Barry CE; Zimmerman M; Dartois V; Savic RM
    PLoS Med; 2019 Apr; 16(4):e1002773. PubMed ID: 30939136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Novel Efflux Proteins Rv0191, Rv3756c, Rv3008, and Rv1667c Involved in Pyrazinamide Resistance in Mycobacterium tuberculosis.
    Zhang Y; Zhang J; Cui P; Zhang Y; Zhang W
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28584158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent rifamycin-sparing regimen cures guinea pig tuberculosis as rapidly as the standard regimen.
    Dutta NK; Alsultan A; Gniadek TJ; Belchis DA; Pinn ML; Mdluli KE; Nuermberger EL; Peloquin CA; Karakousis PC
    Antimicrob Agents Chemother; 2013 Aug; 57(8):3910-6. PubMed ID: 23733473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In Vivo-Selected Pyrazinoic Acid-Resistant Mycobacterium tuberculosis Strains Harbor Missense Mutations in the Aspartate Decarboxylase PanD and the Unfoldase ClpC1.
    Gopal P; Tasneen R; Yee M; Lanoix JP; Sarathy J; Rasic G; Li L; Dartois V; Nuermberger E; Dick T
    ACS Infect Dis; 2017 Jul; 3(7):492-501. PubMed ID: 28271875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide.
    Zhang Y; Scorpio A; Nikaido H; Sun Z
    J Bacteriol; 1999 Apr; 181(7):2044-9. PubMed ID: 10094680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High Systemic Exposure of Pyrazinoic Acid Has Limited Antituberculosis Activity in Murine and Rabbit Models of Tuberculosis.
    Lanoix JP; Tasneen R; O'Brien P; Sarathy J; Safi H; Pinn M; Alland D; Dartois V; Nuermberger E
    Antimicrob Agents Chemother; 2016 Jul; 60(7):4197-205. PubMed ID: 27139472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis.
    Zimhony O; Cox JS; Welch JT; Vilchèze C; Jacobs WR
    Nat Med; 2000 Sep; 6(9):1043-7. PubMed ID: 10973326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Esters of Pyrazinoic Acid Are Active against Pyrazinamide-Resistant Strains of Mycobacterium tuberculosis and Other Naturally Resistant Mycobacteria In Vitro and Ex Vivo within Macrophages.
    Pires D; Valente E; Simões MF; Carmo N; Testa B; Constantino L; Anes E
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7693-9. PubMed ID: 26438493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A quantitative adaptation of the Wayne test for pyrazinamide resistance.
    Meinzen C; Proaño A; Gilman RH; Caviedes L; Coronel J; Zimic M; Sheen P
    Tuberculosis (Edinb); 2016 Jul; 99():41-46. PubMed ID: 27450003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pyrazinamide: the importance of uncovering the mechanisms of action in mycobacteria.
    Stehr M; Elamin AA; Singh M
    Expert Rev Anti Infect Ther; 2015 May; 13(5):593-603. PubMed ID: 25746054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new approach for pyrazinamide susceptibility testing in Mycobacterium tuberculosis.
    Zimic M; Loli S; Gilman RH; Gutierrez A; Fuentes P; Cotrina M; Kirwan D; Sheen P
    Microb Drug Resist; 2012 Aug; 18(4):372-5. PubMed ID: 22372927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and transmission of pyrazinamide resistant Mycobacterium tuberculosis in China.
    Xu P; Wu J; Yang C; Luo T; Shen X; Zhang Y; Nsofor CA; Zhu G; Gicquel B; Gao Q
    Tuberculosis (Edinb); 2016 May; 98():56-61. PubMed ID: 27156619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.